A-DNA

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Retrieved on: 
Thursday, March 28, 2024
Cygnus, Enzyme, Rabies, SAHPRA, Biology, Sale, Innovation, Infection, Note, European, AVATAR, Therapy, Host cell protein, Vaccine, Analysis, Convertible, Research, Biotechnology, A-DNA, Massachusetts General Hospital, Partnership, Melamaravakkadu, Webcast, Primate, RNA, Biofuel, C1, Virology, SME, Safety, Nature Communications, Transferrin, Livestock, Global health, Manuscript, Food, Senior, NIIMBL, Antibody, Hospital, Antigen, Diagnosis, Health, Pithing, RBD, Phibro Animal Health, COVID-19, Dyadic, Messenger, Protein, Human

“In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.

Key Points: 
  • “In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.
  • We believe that we are well-positioned, both financially and scientifically, to execute our strategic plan with enhanced capabilities and resources.
  • For the year ended December 31, 2023, the Company received a total of approximately $1.3 million in connection with the sale of Alphazyme LLC.
  • Other Income: For the year ended December 31, 2023, the Company had a gain of approximately $1,018,000 from the sale of the Company’s equity interest in Alphazyme, LLC.

Kraig Biocraft Laboratories Shares Industry Update on Recombinant Spider Silk from Waste Plastics

Retrieved on: 
Thursday, March 28, 2024
RPI, Dragon silk, ANN, A-DNA, Microorganism, Recycling, Pseudomonas, Microplastics, Polyethylene, Silk, Research, News, Bacteria, Food, Molecular biology, KBLB, Plastic, Rensselaer Polytechnic Institute, OTCQB

ANN ARBOR, Mich., March 28, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"), comments on an exciting advancement in spider silk engineering from the Rensselaer Polytechnic Institute ("RPI").

Key Points: 
  • ANN ARBOR, Mich., March 28, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"), comments on an exciting advancement in spider silk engineering from the Rensselaer Polytechnic Institute ("RPI").
  • Researchers at RPI published a paper in Microbial Cell Factories outlining a new and novel method of creating spider silk protein from waste plastics.
  • Kraig Labs' recombinant spider silk production model utilizes traditional silk production systems involving planting mulberry trees to harvest and feed the leaves to silkworms.
  • The Company's specialized silkworms have been scientifically enhanced through molecular biology to create recombinant spider silk cocoons that are reeled to produce spider silk yarns and fabrics.

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Survival, A-DNA, Patient, Neoplasm, DNA, Biology, AACR, Clinical trial, Skin, Medical imaging

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024.
  • BBI-355 is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) being studied in the ongoing, first-in-human, Phase 1/2 POTENTIATE clinical trial in patients with oncogene amplified cancers.
  • “Extrachromosomal DNA afford unique advantages to tumors, typically rendering existing therapies ineffective and correlating with poor patient outcomes,” said Chris Hassig, Ph.D., Chief Scientific Officer of Boundless Bio.
  • BBI-355 showed substantial antitumor activity, including complete and durable regressions, in preclinical oncogene amplified models.

GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics

Retrieved on: 
Thursday, March 14, 2024
Diagnosis, WGS, P130, HZ, P180, Conference, Genetic testing, SLC16A2, CMA, Patient, Medical genetics, Research, A-DNA, Impact, American College, VUS, Fire, ACMG, Syndrome, GeneDx, Analysis, Medical device

STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.

Key Points: 
  • STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.
  • These findings represent improved data quality from pipeline and platform improvements.
  • Through an industry-sponsored session, GeneDx will explore the gap between the availability of the medical genetics workforce and the genetic testing needs of pediatric patients.
  • "We are motivated to continue to push the boundaries of genomics to transform the future of healthcare," said Paul Kruszka, Chief Medical Officer at GeneDx.

Boundless Bio Announces Pricing of Initial Public Offering

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Genetics, Clinical Trials, Other Health, SVB Securities, Floor, Madison Avenue, Goldman Sachs, A-DNA, Telephone, Patient, DNA, Sale, Attention, Guggenheim, Security (finance), Biology, Guggenheim Partners, Prospectus, Nicollet Mall, State Street

Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share.

Key Points: 
  • Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share.
  • All of the shares are being offered by Boundless Bio.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $100.0 million.
  • In addition, Boundless Bio has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Global Contract Development and Manufacturing Organization Market Analysis Report 2023-2024 and 2029: Flexible and Scalable Manufacturing Processes Shaping the CDMO Landscape - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024
Chemicals, Plastics, Health, Manufacturing, Other Manufacturing, Pharmaceutical, Biotechnology, Catalent, CDMO, Growth, Prevalence, Cardiovascular disease, A-DNA, Application, COVID-19, Patient, Conditional sentence, Samsung Biologics, Research, Diabetes, Messenger, WuXi Biologics, Investment, Antibody, Drug development, Workforce, API, Glaucoma, Vaccine, CMOS, Fine chemical

The global contract development and manufacturing organization (CDMO) market was valued at US$124.38 billion in 2023, and is expected to be worth US$256.90 billion in 2029.

Key Points: 
  • The global contract development and manufacturing organization (CDMO) market was valued at US$124.38 billion in 2023, and is expected to be worth US$256.90 billion in 2029.
  • The "contract development manufacturing organization (CDMO)" model has emerged in response to growing demand.
  • CDMOs, third-party providers, specialize in developing and manufacturing production processes for pharmaceutical firms, offering support throughout the drug-making journey.
  • The growing importance of specialized services, spanning early-stage development to commercial manufacturing, underscores the expanding role of CDMOs in the entire drug development lifecycle.

EQS-News: Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials

Retrieved on: 
Wednesday, March 13, 2024
AMSilk, Protein engineering, A-DNA, AI, Research and development, Molecular biology, PCT, Gold, Gel, Microplastics, CO2, BRAIN, Partnership, Fine chemical

Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials

Key Points: 
  • Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials
    The issuer is solely responsible for the content of this announcement.
  • Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials
    Zwingenberg / Neuried (Germany), March 5, 2024 - BRAIN Biotech AG, leading provider of solutions for the biologization of industry, and AMSilk GmbH, a global leader in advanced materials made from spider silk-based proteins, announce the successful completion of the first phase of a development collaboration.
  • The success of this strategic R&D collaboration is based on the use of BRAIN Biotech’s rational design in protein engineering.
  • With their years of protein engineering expertise and with our common vision, BRAIN Biotech is an ideal fit as a development partner.”

Oxford Nanopore launches PromethION 2 Integrated into open early access

Retrieved on: 
Thursday, March 7, 2024
Health, Genetics, Other Science, General Health, Research, Science, Love, A-DNA, Oxford Nanopore Technologies, NetBurst (microarchitecture), P2i, Animal, Plant, RNA, Early access, Nanopore sequencing, DNA, Video game

Oxford Nanopore Technologies today announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated (P2i) to complete its PromethION product range.

Key Points: 
  • Oxford Nanopore Technologies today announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated (P2i) to complete its PromethION product range.
  • Each flow cell will be capable of delivering the lowest price per Gb for Oxford Nanopore sequencing, providing a rapid and convenient solution for achieving the coverage required for sequencing larger genomes.
  • Since being rolled out in beta access in November 2023, several institutions have put the device to the test with remarkable success.
  • “With the launch of the P2i, Oxford Nanopore is heralding a new era of sequencing technology, offering a fully integrated, plug-and-play device that opens up unparalleled possibilities in both research and applied markets.

Boundless Bio Announces Multiple Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Clinical trial, Poster, Cancer, Patient, Biology, A-DNA, AACR, DNA

Boundless Bio , a clinical-stage, next-generation precision oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced multiple upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, which is being held April 5-10, 2024, in San Diego, CA.

Key Points: 
  • Boundless Bio , a clinical-stage, next-generation precision oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced multiple upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, which is being held April 5-10, 2024, in San Diego, CA.
  • Details of the presentations are as follows:
    Title: Preclinical and clinical pharmacodynamic characterization of BBI-355, a novel, orally bioavailable, and selective CHK1 inhibitor being evaluated in the first-in-human Phase 1/2 POTENTIATE clinical trial of patients with cancer harboring oncogene amplifications

Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing

Retrieved on: 
Wednesday, February 21, 2024
Health, Medical Devices, General Health, Research, Science, Pharmaceutical, Biotechnology, A-DNA, CRL, LEAP, Entrepreneurship, OK, Chemistry, CDMO, Safety, Wheeler, CGMP, Organization, Patient, Portable, IND, Control, CMC, Pharmaceutical industry

Combining Charles River’s industry-leading experience in antibody discovery services, safety, and analytics with Wheeler’s Portable CMC® platform will accelerate therapeutic discovery to IND submission timelines.

Key Points: 
  • Combining Charles River’s industry-leading experience in antibody discovery services, safety, and analytics with Wheeler’s Portable CMC® platform will accelerate therapeutic discovery to IND submission timelines.
  • This umbrella offering efficiently connects the preclinical, clinical manufacturing, and release testing journeys, significantly reducing the complexity of managing multiple vendor relationships.
  • Integrating CMC development early in discovery enables therapeutic developers to collaborate with experts across the organizations to utilize phase-appropriate manufacturing and analytics.
  • Wheeler’s mission is to solve translational challenges inherent in advancing from discovery to CMC development and early-clinical trial material supply.